Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas

Alexander Fort, Nicholas Fort, Camillo Ricordi, Cherie L. Stabler

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (TIDM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.

Original languageEnglish
Pages (from-to)997-1003
Number of pages7
JournalCell Transplantation
Volume17
Issue number9
DOIs
StatePublished - Dec 1 2008

Fingerprint

Medical problems
Islets of Langerhans
Encapsulation
Grafts
Liver
Pancreas
Cells
Technology
Equipment and Supplies
Langerhans Cells
Portal Vein
Type 1 Diabetes Mellitus
Hypoglycemia
Immunosuppression
Cell Survival
Transplantation
Inflammation
Transplants
Therapeutics
Growth

Keywords

  • Bioartificial pancreas
  • Biohybrid device
  • Diabetes
  • Encapsulation

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. / Fort, Alexander; Fort, Nicholas; Ricordi, Camillo; Stabler, Cherie L.

In: Cell Transplantation, Vol. 17, No. 9, 01.12.2008, p. 997-1003.

Research output: Contribution to journalArticle

Fort, Alexander ; Fort, Nicholas ; Ricordi, Camillo ; Stabler, Cherie L. / Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. In: Cell Transplantation. 2008 ; Vol. 17, No. 9. pp. 997-1003.
@article{270d4dd2b7f04cf5acb20306cacb5e46,
title = "Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas",
abstract = "The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (TIDM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.",
keywords = "Bioartificial pancreas, Biohybrid device, Diabetes, Encapsulation",
author = "Alexander Fort and Nicholas Fort and Camillo Ricordi and Stabler, {Cherie L.}",
year = "2008",
month = "12",
day = "1",
doi = "10.3727/096368908786991498",
language = "English",
volume = "17",
pages = "997--1003",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas

AU - Fort, Alexander

AU - Fort, Nicholas

AU - Ricordi, Camillo

AU - Stabler, Cherie L.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (TIDM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.

AB - The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (TIDM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.

KW - Bioartificial pancreas

KW - Biohybrid device

KW - Diabetes

KW - Encapsulation

UR - http://www.scopus.com/inward/record.url?scp=62549084765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549084765&partnerID=8YFLogxK

U2 - 10.3727/096368908786991498

DO - 10.3727/096368908786991498

M3 - Article

VL - 17

SP - 997

EP - 1003

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -